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Protein-based markers that classify tumor subtypes and predict therapeutic response would be clinically useful in guiding patient
treatment. We investigated the LC-MS/MS-identiﬁed protein biosignatures in 39 baseline breast cancer specimens including 28
HER2-positive and 11 triple-negative (TNBC) tumors. Twenty proteins were found to correctly classify all HER2 positive and 7
of the 11 TNBC tumors. Among them, galectin-3-binding protein and ALDH1A1 were found preferentially elevated in TNBC,
whereas CK19, transferrin, transketolase, and thymosin β4a n dβ10 were elevated in HER2-positive cancers. In addition, several
proteins such as enolase, vimentin, peroxiredoxin 5, Hsp 70, periostin precursor, RhoA, cathepsin D preproprotein, and annexin 1
were found to be associated with the tumor responses to treatment within each subtype. The MS-based proteomic ﬁndings appear
promising in guiding tumor classiﬁcation and predicting response. When suﬃciently validated, some of these candidate protein
markers could have great potential in improving breast cancer treatment.
1.Introduction
Chemotherapy has long been used to treat all types of
cancer. Although survival beneﬁts from adjuvant systemic
chemotherapy in breast cancer have been thoroughly doc-
umented [1], success is not uniform with many still dying
after the initial chemotherapy. The unpredictable tumor
response to chemotherapy in any given patient and the
signiﬁcant toxicity manifested in all demand a better strategy
for delivering cancer therapy.
In selective subtypes of breast cancer, therapies targeting
speciﬁc signal transduction and/or metabolic pathways have
been successful. For example, Herceptin for HER2/neu pos-
itive breast cancer [2, 3] and poly(ADP ribose) polymerase
(PARP) inhibitors for triple-negative breast cancer with
defectiveDNA-repair[4,5]areamongtherecentsuccessesof
targeted therapy. The success of target therapy has led to an
explosion of interest in developing tailored systemic therapy.
Breast cancer is a heterogeneous disease molecularly, his-
tologically, and clinically. Clinical outcomes from the same
treatment vary widely even among patients with tumors
of identical stage and histology. Breast cancers developed
from an accumulation of genetic alterations may partially
explain the diﬀerences observed including tumor responses2 International Journal of Proteomics
to anticancer agents [6]. Recently gene expression analysis
has identiﬁed ﬁve subtypes of breast cancer which overlaps
with clinical tumor classiﬁcation according to the expression
of three biomarkers, estrogen receptor (ER), progesterone
receptor (PR), and epidermal growth factor receptor 2
(HER2). Clinically these three markers are prognostically
and therapeutically important in guiding treatment selection
[7–10]; however, they do not fully reﬂect the complexity and
heterogeneity of breast cancer and do not always predict
the outcome of the treatment. For example, Herceptin as
a single agent or in combination with chemotherapy has
been shown to reduce recurrent disease and to save lives in
patients with HER2-positive breast cancer, yet a signiﬁcant
number of HER2 overexpression tumors do not respond to
thetreatment[11].Additionalmoleculartargetsareexpected
to improve tailored treatment in the future.
Proteomics has been employed in recent years to identify
new disease-related biomarkers for cancer diagnosis and
implementation of tailored treatment [12–15]. The tumor
proteomes representing a global protein expression of cancer
may provide new insights into the molecules that govern
the dynamic cellular activities of tumor cells. Therefore, we
choose to study breast tumor protein signatures in breast
cancer classiﬁcation and in predicting tumor response to
treatment.
Previously we used SELDI mass spectrometry to proﬁle
tumor response to neoadjuvant treatment and found that
signiﬁcant m/z proﬁle diﬀerences existed between cancers
of nonresponders (tumor regression rate ≤25%) and others
(tumor regression rate >25%) [16]. In this current study we
have applied the LC-MS/MS technology to study the breast
cancer proteomes in human tissues and identify unique
proteins that may have the potential to separate two subtypes
of breast cancer (TNBC versus HER2+) and to predict drug
responses within each subtype.
2.MaterialsandMethods
2.1. Collection of Breast Tumor Tissues and Classiﬁcation
of Response. Breast tumors were collected, processed, and
banked as previously described [16]. This study was ap-
proved by the UCLA institutional review board (IRB).
Tumors from 39 consented patients with locally advanced
breast cancer were collected from a neoadjuvant clinical trial
[17]. Eleven were triple-negative breast tumors (TNBC, ER-
/PR-/HER2-), and 28 were HER2-positive tumors (HER2+).
The tumor specimens were uniformly collected according to
astandardoperatingprocedureestablishedinourlaboratory.
Baseline tumor specimens were obtained by either core
needle biopsy or surgical biopsy before starting the neoadju-
vant Taxotere/Carboplatin/±Herceptin treatment (TC ± H).
Evaluation of tumor response to the treatment was measured
both by pathologic examination of surgically removed tissue
and by clinical assessment including physical examina-
tion and/or imaging studies. The pathological response of
the tumor was reported as either pathologically complete
response (pCR) or having residual tumor. Because a baseline
tumor size by pathologic evaluation was not possible in
patients receiving neoadjuvant treatment, the clinically or
imaging-measured tumor size prior to chemotherapy was
used as the baseline tumor size. Pathological assessment after
chemotherapy including tumor size, lymph node staging,
and tumor biomarkers was performed on the specimen
obtained from the deﬁnitive breast cancer surgery [16].
The tumor regression rate (TRR) was used to evaluate
tumor response induced by neoadjuvant therapy, and it was
calculated as follows: (baseline tumor size − residual tumor
size)/baseline tumor size × 100%, where the baseline tumor
size was measured clinically, and the postchemotherapy
residual invasive tumor size was measured pathologically.
The tumor response was categorized into three groups:
responders (TRR > 75%, R), intermediate responders
(25% < TRR ≤ 75%, IR), and nonresponders (TRR ≤ 25%,
NR).
2.2. Protein Extraction and Abundant Protein Depletion.
Protein extraction from tumors and depletion of abundant
proteins from tumor lysates were performed as previously
described [16]. Brieﬂy, frozen tumors were homogenized
in liquid nitrogen and suspended in 1% Triton X-100.
The samples were refrozen at −80◦C and thawed on ice
twice. Following centrifugation (10,000g, 10min, 4◦C), the
supernatants were subjected to albumin and immunoglob-
ulin depletion using an albumin and IgG removal kit
(Amersham) as well as hemoglobin depletion using Ni-NTA
magnetic agarose beads (Qiagen). Protein concentrations of
each preparation were determined by the BioRad protein
assays.
Because the blood proteins in the breast cancer tissue can
causesigniﬁcantionsuppression oflowerabundancecancer-
related proteins/peptides which may mask ion signals of less
abundant peptides with similar M/Z ratios and retention
times. In addition, the over presentation of serum proteins
in the specimen may lower the amount of the cancer-related
proteins available for LC-MS/MS analysis [18]. As a result,
selected abundant serum proteins were depleted from the
tissue extracts. Our preliminary test has shown more than
95% albumin, IgG and hemoglobin were removed by the
described method, and more meaningful proteins have been
detected.
2.3. Trypsin Digestion. The dried protein samples were
dissolved in 6M guanidine HCl, reduced with DTT (5mM–
15mM),andalkylatedusing10mMiodoacetamide.Samples
were then diluted with NH4HCO3 to lower guanidine HCl
concentration (1M), mixed with trypsin (1:50w/w ratio,
sequencing grade, Promega) containing 50mM ammonium
bicarbonate, and incubated at 37◦C overnight. Samples were
desalted by C18 Microspin columns (The Nest Group), and
the eluates were dried in a vacuum centrifuge.
2.4. LC-MS/MS Analysis. Each digested and dried sample
was prepared for LC-MS/MS analysis as previously reported
[19]. Brieﬂy the samples were redissolved in Buﬀer A
(H2O/acetonitrile/formic acid, 98.9/1/0.1, typically at 0.7μg
protein/uL), and aliquots were injected (5μL) onto anInternational Journal of Proteomics 3
in-house-prepared C18 trap. The retained materials were
placed onto a reverse phase column (New Objective C18,
15cm, 75μM diameter, 5μm particle size equilibrated
in Buﬀer A) and eluted (300nL/min, Eksigent Nanolc-
2D) with an increasing concentration of Buﬀer B (ace-
tonitrile/water/formic acid, 98.9/1/0.1;min/%B: 0/5, 10/10,
112/40, 130/60, 135/90, 140/90). Eluted peptides were ana-
lyzed by MS and data-dependent MS/MS (collision-induced
dissociation) using online data-dependent tandem mass
spectrometry (LTQ Orbitrap, Thermo Fisher Scientiﬁc) in
which the seven most abundant precursor ions were selected
for MS/MS. Before testing the experimental specimens, the
reproducibility of LC-MS/MS analysis was conﬁrmed by
examining the triplicates of two diﬀerent tissue samples, and
similar proteins were identiﬁed from the triplicates of each
sample with more than 90% overlapping.
2.5. Database Searching and Analysis. BioWorks software
(version 3.3.1, Thermo Fisher Sceintiﬁc), based on the
SEQUEST algorithm (SRF v.5, Thermo Fisher Scientiﬁc),
was used to search the mass spectra against a human
trypsinindexeddatabase(human.fasta.hdrdatabase,Version
12.2, 227246 entries) as described by Whelan et al. [19].
SEQUEST was searched with a fragment ion mass tolerance
of 1.00Da and a parent ion tolerance of 50PPM. The search
tolerated up to two missed trypsin cleavages with variable
modiﬁcations for carboxyamidomethylation (57.02146Da)
and methionine oxidation (15.99492Da). Scaﬀold (version
3.0.3, Proteome Software, Inc.) was used to validate MS/MS-
based peptide and protein identiﬁcations. Peptide identiﬁca-
tions were accepted if they could be established at greater
than 95.0% probability as speciﬁed by the Peptide Prophet
Algorithm [20]. Protein identiﬁcations were accepted if they
could be established with a greater than 99.0% probability
and contained at least 2 identiﬁed peptides. Protein proba-
bilities were assigned by the Protein Prophet Algorithm [21].
From the resulting MS/MS protein identiﬁcations, a list
of proteins was generated for each sample. A list of semi-
quantitative protein abundances in the diﬀerent samples
was developed using the normalized spectrum counts of the
identiﬁed tryptic peptides from each protein, as compiled
by the Scaﬀold program. The protein lists and their rela-
tive abundances were then compared to ﬁnd diﬀerentially
expressed proteins between two groups.
2.6. Statistic Analysis. The data ﬁles exported from Scaﬀold
were further processed as Excel ﬁles. The top 60% (180)
abundant proteins of the 315 identiﬁed proteins were further
selected for hierarchical clustering and supervised classiﬁca-
tionstudies.Thoseproteinswithatleasta2-folddiﬀerencein
mean spectral counts between any two groups were selected
for analysis in the web-based Gene Expression Proﬁle
Analysis Suite (GEPAS, version 4.0, http://www.gepas.org).
Five diﬀerent classiﬁcation algorithms were tested to select
candidate markers in the GEPAS software: Support Vector
Machines (SVM), K-Nearest Neighbor Clustering (KNN),
Diagonal Linear Discriminant Analysis (DLDA), Prediction
Analysis with Microarrays (PAM), and Self-Organizing Map
(SOM).
2.7. Immunohistochemistry Staining. As m a l lp o r t i o no fe a c h
of the baseline tumors was embedded in OCT and stored
at −80◦C. Endogenous peroxidase activity was quenched
with 0.6% hydrogen peroxide in methanol for 10 min-
utes, and endogenous biotin was eliminated by Biotin
Blocking System (DAKO, x0590). After blocking with 1:5
diluted normal goat serum or fetal bovine serum, slides
were incubated for 1 hour with primary antibody (CK19,
mouse IgG, ready to use, DAKO; galectin-3-binding pro-
tein, Goat IgG, 1:200 dilution, R&D) and 30 minutes
with biotinylated secondary antibody (biotinylated anti-
mouse Ig, 1:800 dilution, DAKO; biotinylated anti-goat Ig,
1:200 dilution, Vector Labs). Antigen-antibody complexes
were then detected by the StreptABComplex/HRP method
(DAKO)usingdiaminobenzidineasachromogenicsubstrate
(DAKO). Immunostained slides were lightly counterstained
with hematoxylin. For negative controls, primary antibodies
were replaced by mouse IgG or goat IgG.
3. Results
3.1. Patient Characteristics. The reported thirty-nine base-
line tumor specimens included 28 HER2-positive breast
cancers and 11 TNBC with HER2 status determined by
ﬂuorescence in situ hybridization (FISH) assay. Fifteen of
the 28 HER2+ patients were randomized to receive TC, and
the remaining 13 received TC and Herceptin (TCH) before
surgery. All eleven patients with TNBC received neoadjuvant
TC. Following the neoadjuvant treatment, 28 patients with
HER2+ tumors showed 12 responders (R), including 7 with
pathological complete response (pCR) and 5 with a tumor
regression rate >75%, 12 intermediate responders (IR), and
4 nonresponders (NR). In the TNBC group, there were 7
responders including 6pCR and 1 with tumor regression
rate >75%, 3 IR, and 1 NR. The clinical characteristics and
pathologic features of the 11 TNBC and 28 HER2+ cases are
summarized in Tables 1(a) and 1(b).
3.2. Protein Comparison between HER2+ and TNBC Groups.
Proteins identiﬁed by MS/MS from the 39 tumors showed
that 48 proteins were only found in HER2+ tumors, 24 were
only seen in TNBC, and 243 proteins were shared by both,
but the quantity of the shared proteins diﬀered widely in the
two tumor types. In this study, we focused the analysis on
the top 60% abundant proteins (180/315) detected in the 39
tumors.
The 20 most abundant shared proteins by both sub-
types of cancer were summarized in Table 2. Among them
apolipoprotein A-I and D, enolase 1, tumor rejection antigen
(gp96) 1, transgelin 2, coﬁlin 1, proﬁlin, heat shock proteins
70, and annexins 5 were found to be present in signiﬁcant
quantity in both types of breast cancer. Some of these shared
proteins found in suﬃcient amount may be useful for breast
cancer detection.4 International Journal of Proteomics
Table 1
(a) Clinical characteristics of 11 TNBC tumors
LTQ Orbitrap sample ID Patient age Ethnicity TR % Response T stage Histological type ER PR FISH R/G ratio Neoadjuvant
#1 61 White 80 R T3 IDC −− 1.10 TC
#2 29 Hispanic −60 NR T3 IDC −− 0.92 TC
#5 55 Hispanic 100 R (pCR) T3 IDC −− 0.92 TC
#6 54 Hispanic 100 R (pCR) T3 IDC −− 1.01 TC
#7 40 Asian 45 IR T3 IDC −− 1.17 TC
#8 44 White 100a R (pCR) T3 IDC −− 1.00 TC
#9 49 Hispanic 48 IR T4 IDC −− 1.10 TC
#10 53 White 100 R (pCR) T3 IDC −− 1.20 TC
#11 84 Asian 100 R (pCR) T4 IDC −− 1.03 TC
#36 45 Hispanic 30 IR T3 IDC −− 1.27 TC
#37 38 White 100 R (pCR) T2 IDC −− 1.10 TC
aLN positive without residual primary cancer.
(b) Clinical characteristics of 28 HER2+ tumors
LTQ Orbitrap sample ID Patient age Ethnicity TRR % Response T stage Histological type ER PR FISH R/G ratio Neoadjuvant
#17 38 White 40 IR T3 IDC + − 12.4 TC
#18 63 Asian 100 R (pCR) T3 IDC + − 12.7 TCH
#19 57 White 100 R (pCR) T3 IDC −− 4.6 TC
#20 56 Asian 78.2 R T4 IDC + − 10.71 TC
#21 51 Black 56 IR T3 IDC −− 19.97 TCH
#22 31 White 45.5 IR T3 IDC + + 2.2 TC
#23 55 White 80 R T4 IDC + + 3.8 TC
#24 45 Asian 75 IR T4 IDC + + 2.7 TCH
#25 42 Hispanic 63.5 IR T4 IDC + − 2.5 TC
#26 50 White 67.1 IR T3 IDC −− 2.41 TCH
#27 33 White 82.9 R T3 IDC + + 3.03 TCH
#28 40 White 66.7 IR T3 IDC −− 8.1 TC
#29 35 Hispanic 100a R (pCR) T3 IDC −− 42.2 TCH
#30 44 White 97.3 R T4 IDC −− 4.2 TC
#31 30 White −7.7 NR T3 IDC + − 5T C
#32 57 White 25% NR T4 IDC + − >4T C H
#33 37 White 33.3 IR T2 IDC + + 9.49 TC
#34 36 Black 25 NR T3 IDC −− 5.1 TC
#35 42 White 60 IR T2 IDC + + 4.5 TCH
#38 55 White 42.3 IR T4 IDC −− 3.9 TCH
#39 47 White 100b R (pCR) T3 IDC + + >20 TCH
#40 50 Asian 100b R (pCR) T3 IDC + + 4.19 TCH
#41 58 White 50 IR T4 IDC + + 2.1 TCH
#42 40 Asian 60 IR T2 IDC −− 16 TC
#43 37 White −85.6 NR T3 IDC + + 3.1 TC
#44 49 White 100b R (pCR) T2 IDC + − 7.7 TCH
#45 55 Asian 92.6 R T3 IDC −− 9.9 TC
#46 41 Hispanic 100 R (pCR) T2 IDC −− 9.2 TC
aLN positive and residual DCIS; bresidual DCIS only.International Journal of Proteomics 5
Table 2: The 20 most abundant proteins shared by both HER2-
positive and TNBC tumors.
Identiﬁed proteins Accession
no. MW
Apolipoprotein A-I gi|90108664 28kDa
Vimentin gi|62414289 54kDa
Enolase 1 gi|4503571 47kDa
Alpha-1 antitrypsin gi|157086955 45kDa
Triosephosphate isomerase 1 gi|4507645
(+2) 27kDa
Cyclophilin A gi|1633054 18kDa
Apolipoprotein D gi|619383 28kDa
Coﬁlin 1 gi|5031635 19kDa
Chaperonin gi|31542947 61kDa
Transgelin 2 gi|4507357 22kDa
Heat shock 70kDa protein 5 gi|16507237 72kDa
Tumor rejection antigen (gp96) 1 gi|4507677 92kDa
S100 calcium-binding protein A11 gi|5032057 12kDa
Lumican precursor gi|4505047 38kDa
Tropomyosin 4 gi|4507651 29kDa
ATP synthase, H+ transporting,
mitochondrial F1 complex gi|32189394 57kDa
Prosaposin isoform a preproprotein gi|11386147 58kDa
Proﬁlin gi|157838211
(+4) 15kDa
Heat shock 70kDa protein 8 isoform 1 gi|5729877 71kDa
Annexin 5 gi|4502107 36kDa
Of the 180 top abundant proteins observed in the 39
breast cancer specimens, 61 were found to have a ≥2-fold
diﬀerence of spectrum counts between the two subtypes
of breast cancer (HER2+ versus TNBC). Because some of
these proteins were not detected in every sample, we further
reﬁned the list of diﬀerential proteins by selecting only those
detectedin ≥50%ofthecasesineithergroup.Theselected44
diﬀerentially expressed proteins were tested by hierarchical
clustering to classify HER2+ breast cancer versus TNBC.
These diﬀerentially expressed proteins correctly classiﬁed all
28 HER2+ tumors and 8 of the 11 TNBC by unweighted
pair-group method using arithmetic average (UPGMA)
(Figure 1).
Self-validation of selected proteins in tumor classiﬁ-
cation was tested using a supervised classiﬁcation. The
44 diﬀerentially expressed proteins were used to build a
model separating subtypes of the tumors by Prophet, a web
interface from the Gene Expression Proﬁle Analysis Suite.
Error rates were calculated as the number of misclassiﬁed
tumors divided by total tumor cases tested. The error rates
usingvariousnumbersofproteinsbydiﬀerentmodels(SVM,
KNN, DLDA, PAM, and SOM) were estimated by leaving-
one-out tests (see File A in Supplementary Material available
online at doi:10.1155/2011/896476). SVM had the lowest
error rate (10%, 4/39) with 90% accuracy in tumor classi-
ﬁcation. The top 20 protein candidates (Table 3) selected by
SVM model successfully classiﬁed all 28 HER2+ tumors and
7 of the 11 TNBC. Among the 20 diﬀerentially expressed
proteins, G3BP, ALDH1A1, and complement component 1
inhibitor overexpression were found to be associated with
TNBCsubtype,whereasoverexpressionofCK19,transferrin,
transketolase, and thymosin β4a n dβ10 were associated with
HER2+ tumors (Figure 2).
3.3. Proteins Correlated with Diﬀerent Tumor Response to
Neoadjuvant Treatment among HER2+ Tumors. Of the 28
HER2+ tumors, there were 12 R (including 7 with pCR), 12
IR, and 4 NR. We compared proteomic diﬀerences between
the two groups with extreme tumor response (pCR and NR)
and found that 48 of the 180 proteins had an expressional
diﬀerence ≥2-fold between 7 pCR versus 4 NR tumors. Self-
validation of these potential marker proteins by ﬁve super-
vised classiﬁcation methods suggested that the KNN had the
lowest error rate (9%, 1/11) in predicting tumor response
(Files B and C). By using KNN = 1 method, 100% (4/4)NR
and 85.7% (6/7)pCR were correctly grouped by 20 selected
proteins (Table 4). Of the 20 proteins, overexpressions of
enolase1, vimentin, and L-plastin in HER2-positive tumors
were associated with pCR, whereas high level of heat shock
proteins 70 (Hsp70) and peroxiredoxin 5 (Prx V) were found
only in the NR cases.
3.4.ProteinsPredictingTNBCTumorResponsetoNeoadjuvant
Treatment. Among the 11 TNBC cases, there were 7R
(including 6 pCR), 3 IR, and 1 NR. Due to the small
sample size, the proteins of responders’ tumor (R) were
compared to all the remaining tumors with less response
(IR + NR). Sixty-three of 180 proteins had a ≥2-fold mean
diﬀerences between the two groups of TNBC with diﬀerent
response to the same treatment. Self-validation of these
proteins by ﬁve supervised classiﬁcation methods was used
to compare the accuracy in predicting a tumor response.
Using DLDA method, 6 of 7 tumors in the R group and 3
of 4 tumors in IR/NR group were correctly classiﬁed by the
30 selected proteins (error rate 18%) (Files D and E). Of
these 30 proteins, the increased heat shock 70kDa protein
8, periostin, Ras homolog gene family member A (RhoA),
actinin alpha 4, cathepsin D preproprotein, annexin 1, and
several other proteins were associated with drug resistance in
TNBC (Table 5).
3.5. Evaluation of CK19 and G3BP Expression in TNBC and
HER2+ Frozen Tumors. CK19 and G3BP protein expressions
were tested in breast cancer tumors by immunohisto-
chemistry. The CK19 and G3BP staining showed cyto-
plasmic/membrane staining pattern in breast cancer cells.
The overexpression of CK19 was found in HER2+ breast
tumors (Figure 3) while the expression of G3BP was found
to be upregulated in most TNBC (Figure 4). The concor-
dance ﬁndings between the mass spectrometry analysis and
immunohistochemical staining of the same tumor suggested
that high-throughput mass spectrometry may be used as a
screening tool to discover disease-related biomarkers.6 International Journal of Proteomics
Table 3: Top 20 diﬀerentially expressed proteins selected by supervised classiﬁcation methods for classifying two tumor subtypes.
Rank Accession no. Protein name MW HER2+/TNBC
mean
Subcellular
location Function
1g i |10946578 Thymosin β45 k D a 2 . 9 9 Cytoplasm,
cytoskeleton
For cytoskeletal binding, involved in cell
growth and maintenance
2g i |4507521 Transketolase 68kDa 4.20 Cytosol Involved in metabolism. Associated with cell
proliferation of uterine and cervical cancer.
3g i |1633054 Cyclophilin A 18kDa 2.45 Cytoplasma Involved in accelerate the folding of proteins
4g i |73858568 Complement
component 1 inhibitor 55kDa 0.33 Secreted Regulating the complement cascade
5g i |4557871 Transferrin 77kDa 16.38 Secreted Essential for cell growth and iron-dependent
metabolic processes
6g i |90111766 Keratin type I
cytoskeletal 19 44kDa 11.29 Cytoskeleton Involved in metastatic progression of breast
cancer
7g i |10863895 Thymosin β10 5kDa 2.25 Cytoplasm,
cytoskeleton
For cytoskeletal binding, involved in cell
growth and maintenance
8g i |5031863 Galectin-3-binding
protein 65kDa 0.41 Secreted Modulating cell-cell and cell-matrix
interactions
9 gi|4505753
(+1)
Phosphoglycerate
mutase 1 29kDa 2.51 Cytosol Involved in glycolysis
10 gi|5174391 Aldo-keto reductase
family 1, member A1 37kDa 0.30 Cytosol Involved in the reduction of biogenic and
xenobiotic aldehydes
11 gi|21361176 Aldehyde dehydrogenase
1A1 55kDa 0.39 Cytoplasm
Detoxifying enzyme responsible for
oxidating of intracellular aldehydes. A
marker for cancer stem cells
12 gi|4505185 Macrophage migration
inhibitory factor 12kDa 0.36 Secreted,
cytoplasm Involved in integrin signaling pathways
13 gi|4507645
(+2)
Triosephosphate
isomerase 1 27kDa 2.49 Cytosol,
nucleus
Fatty acid biosynthesis, gluconeogenesis,
glycolysis, lipid synthesis
14 gi|4930167 Aldolase A 39kDa 6.41 Extracellular,
cytoskeleton Involved in glycolysis
15 gi|116241280
Adenylyl
cyclase-associated
protein 1 (CAP 1)
52kDa 3.03 Membrane Regulating ﬁlament dynamics, cell polarity
and signal transduction,
16 gi|21624607
(+5) Coactosin-like 1 16kDa 0.42 Cytoplasm,
cytoskeleton Regulating the actin cytoskeleton
17 gi|160420317 Filamin A, alpha
isoform 2 281kDa 3.10 Cytoplasm
Anchoring transmembrane proteins to the
actin cytoskeleton, scaﬀold for cytoplasmic
signaling proteins
18 gi|6005942 Valosin-containing
protein 89kDa 3.26 Cytosol,
nucleus
Fragmentation of Golgi stacks during
mitosis and reassembly
19 gi|5174539 Cytosolic malate
dehydrogenase 36kDa 2.52 Cytoplasm Involved glycolysis, oxidation reduction,
and tricarboxylic acid cycle
20 gi|33286418
(+2) Pyruvate kinase 3 58kDa 6 Cytoplasm,
nucleus Involved in glycolysis
4. Discussion
In this discovery study, the MS-detected proteomic dif-
ferences between two subtypes of breast cancer (HER2+
versus TNBC tumors) were explored, and proteomic predic-
tion of tumor response to neoadjuvant chemotherapy was
investigated. LC-MS/MS data sets of proteins from the 39
tumors analyzed allowed us to identify several candidate
proteins that could classify tumor subtypes and predict
tumor response to neoadjuvant chemotherapy.
Two clinical subtypes of breast cancer, HER2-positive
and triple-negative breast cancers, deﬁned by immunohisto-
chemical staining and ﬂuorescence in situ hybridization of
three biomarkers of breast cancer have also been conﬁrmed
by gene analysis as two distinctive types of breast cancer. In
this study, we reported that proteomic analysis could also
separate the two subtypes by the unique biosignature associ-
atedwitheachtypeofbreastcancer(Table 3).Wealsoreport-
ed the potential of proteomic analysis in classifying drug-
resistant TNBC and HER2+ breast cancer (Tables 4 and 5).International Journal of Proteomics 7
Table 4: Top 20 proteins predicting tumor response to neoadjuvant treatment in HER2-positive tumors.
Rank Protein name Accession no. pCR/NR
mean
Subcellular
location Function
1 Enolase 1 gi|4503571 2.59 Cytoplasm, cell
membrane Multifunctional enzyme
2
Heterogeneous nuclear
ribonucleoprotein
A2/B1 isoform B1
gi|14043072 3.51 Nucleus,
cytoplasm Pre-mRNA processing
3 Heat shock 70kDa
protein 1 gi|75061728 0.24 Cytoplasm Stress response
4 Vimentin gi|62414289 9.94 Cytosol Class III intermediate ﬁlaments
5 Vesicle amine transport
protein 1 gi|18379349 0.50 Cytoplasmic
vesicle membrane Neurotransmitter transport
6 Coronin, actin-binding
protein, 1A gi|5902134 2.00 Cytoplasm Component of the cytoskeleton of highly
motile cells
7 Fatty acid-binding
protein 4
gi|4557579
(+1) 0.23 Cytoplasm,
nucleus Lipid transport protein
8 Peroxiredoxin 5 gi|15826629 0.37
Mitochondrion,
cytoplasm,
peroxisome
Antioxidant, oxidoreductase peroxidase
9 Heat shock 70kDa
protein 9 gi|24234688 0.15 Mitochondrion Control of cell proliferation and cellular aging
10 Leucine aminopeptidase
3 gi|41393561 2.94 Cell membrane,
secreted Cell-cell signaling
11 Apolipoprotein D gi|619383 2.90 Secreted Lipid metabolic process
12 L-plastin gi|4504965 3.14 Cytoplasm, cell
membrane
Activation of T cells, intracellular protein
transport
13
Anterior gradient
protein 2 homolog
precursor
gi|5453541 0.11
Secreted,
endoplasmic
reticulum
Mucus secretion
14 Heat shock 10kDa
protein 1 gi|4504523 0.37 Mitochondrion Stress response
15
ATP synthase, H+
transporting,
mitochondrial F1
complex
gi|4757810 0.41 Mitochondrion Proton-transporting ATP synthase complex
assembly
16 Glutathione transferase gi|20664358
(+5) 3.29 Cytoplasm Glutathione metabolic process
17 Chaperonin gi|31542947 0.33 Mitochondrion Stress response
18 Complement
component 3 precursor gi|115298678 3.00 Secreted Activation of the complement system
19
Heterogeneous nuclear
ribonucleoprotein D
isoform a
gi|14110420 2.19 Nucleus,
cytoplasm Transcription regulation
20 Malate dehydrogenase gi|6648067
(+1) 0.22 Cytoplasm Tricarboxylic acid cycle
Through an extensive literature review, some of the iden-
tiﬁed proteins have reported roles that are relevant to cancer
biology and treatment. In TNBC tumors, we observed that
the levels of G3BP, ALDH1A1, and complement component
1 inhibitor protein were preferentially elevated. All of them
have been reported to have important biological properties
in cancer progression. G3BP, also known as 90-kDa Mac-2-
binding protein, is a member of the beta-galactoside-binding
protein family and has a role in modulating cell-cell and
cell-matrix interactions. It has been shown that G3BP is
overexpressed in a variety of cancer cells such as colon,
gastric, and breast cancer, and its overexpression appears
to correlate with tumor progression, and metastasis [22–
26]. Our report is the ﬁrst to describe G3BP overexpression
in human TNBC by both mass spectrometry analysis and
immunohistochemical staining method.
One protein correlated with triple-negative breast cancer
meriting a discussion is ALDH1A1, a detoxifying enzyme
responsible for oxidizing intracellular aldehydes. This pro-
cess is important in early diﬀerentiation of stem cells8 International Journal of Proteomics
Table 5: Top 30 proteins predicting tumor response to neoadjuvant chemotherapy in TNBC tumors.
Rank Protein name Accession no. R/IR + NR
mean Subcellular location Function
1 Heat shock 70kDa protein
8i s o f o r m1 gi|5729877 0.32 Stress response
2
Periostin precursor (PN)
(osteoblast-speciﬁc factor
2)
gi|93138709 0.31 Nucleus Transcription regulation
3 Cyclophilin A gi|1633054 0.41 Secreted Cell attachment adhesion and spreading
4
Tyrosine 3/tryptophan
5-monooxygenase
activation protein
gi|5803225
(+1) 3.71 Nucleus Protein binding
5 Proﬁlin gi|157838211
(+4) 0.32 Cytoplasm,
cytoskeleton Actin cytoskeleton organization
6 Cardiac muscle alpha
actin 1 proprotein gi|4885049 0.08 Cytoplasm,
cytokeleton actin ﬁlament-based movement, apoptosis
7B e t a a c t i n g i |4501885 0.22 Cytoplasm,
cytokeleton Cell motility
8C a l d e s m o n ( C D M ) g i |2498204 0.42 Cytoplasm,
cytokeleton Actin- and myosin-binding protein
9 Tubulin β5g i |7106439 0.19 Cytosol Major constituent of microtubules
10 Tropomyosin 2 (beta)
isoform 1 gi|42476296 0.11 Cytoplasm,
cytokeleton Binding to actin ﬁlaments
11 Actinin, α4g i |12025678 0.11 Nucleus, cytoplasm Protein transport
12 Ras homolog gene family,
member A (RhoA)
gi|10835049
(+4) 0.33 Cytoplasm, cell
membrane Regulating a signal transduction pathway
13 Heterogeneous nuclear
ribonucleoprotein K gi|13384620 0.33 Cytoplasm, nucleus Pre-mRNA-binding proteins
14 Tubulin α1g i |6755901 0.36 Cytosol Major constituent of microtubules
15 Tropomyosin 4 gi|4507651 0.35 Cytoplasm,
cytokeleton Binds to actin ﬁlaments
16 Complement component
1 inhibitor precursor gi|73858568 4.57 Secreted Complement pathway
17
ATP synthase, H+
transporting,
mitochondrial F1 complex
gi|4757810 0.43 Mitochondrion Proton-transporting ATP synthase complex
assembly
18 Calnexin precursor gi|10716563 0.42
Endoplasmic
reticulum
membrane, cell
membrane
Calcium-binding protein
19 Eukaryotic translation
elongation factor 1 alpha 1 gi|4503471 0.29 Cytoplasm Protein biosynthesis
20 Annexin I gi|4502101 0.25 Nucleus, cytoplasm,
membrane Calcium/phospholipid-binding protein
21 Triosephosphate
isomerase 1
gi|4507645
(+2) 0.35 Cytosol, nucleus Fatty acid biosynthesis, gluconeogenesis,
glycolysis, lipid synthesis
22 Cathepsin D
preproprotein gi|4503143 0.35 Lysosome proteolysis
23 Alpha glucosidase II alpha
subunit isoform 2 gi|38202257 0.19 Cytosol Glycan metabolism, N-glycan metabolism
24
Tyrosine
3-monooxygenase/
tryptophan
5-monooxygenase
activation protein
gi|4507949
(+1) 0.42 Nucleus Protein binding
25 Thymosin β10 gi|10863895 0.42 Cytoplasm,
cytokeleton cytoskeleton organizationInternational Journal of Proteomics 9
Table 5: Continued.
Rank Protein name Accession no. R/IR + NR
mean Subcellular location Function
26 Aconitase 2 precursor gi|4501867 0.44 Mitochondrion Carbohydrate metabolism, tricarboxylic
acid cycle
27
Heterogeneous nuclear
ribonucleoprotein D
isoform a
gi|14110420 0.48 Nucleus, cytoplasm Transcription regulation
28 Serine (or cysteine)
proteinase inhibitor gi|32454741 0.25 Secreted Inhibits activated protein C, plasminogen
activator
29 Lumican precursor gi|4505047 0.28 Secreted Binds to laminin
30 Apolipoprotein D gi|619383 2.86 Secreted Transport
Nucleolin 
Macrophage migration inhibitory factor 
Moesin
Aldo-keto reductase family 1, member 
Gelsolin isoform a precursor 
Galectin- 3- binding protein 
Coactosin-like 1
L-plastin
Inter-alpha-trypsin inhibitor heavy chain  precursor
Aldehyde dehydrogenase 1A1 
Complement component 1 inhibitor precursor
Orosomucoid  1 precursor
Major histocompatibility complex class I HLA-A29.1
HLA class I histocompatibility antigen, alphalin precursor
Fatty acid-binding protein 4
Cytokeratin-19
Keratin 8 
Keratin 18 
Human enoyl-coenzyme A
Phosphoglycerate mutase 1 
Triosephosphate isomerase 1
Aldolase
Tubulin, beta  5
Eukaryotic translation elongation factor 1 alpha 1
Human platelet proﬁlin
Pyruvate kinase 3 isoform 1
Phosphoglycerate kinase 1
GAPDH
Endothelial cell growth factor 1 precursor 
Eukaryotic translation elongation factor 2
Human rab GDI 
Cytosolic malate dehydrogenase
Transketolase 
Cyclophilin A 
Filamin A,alpha isoform 2
Thymosin, 4
Adenylyl cyclase-associated protein 1 (CAP  1)
Heat shock 90kDa protein 1, beta 
Valosin-containing protein
Prosaposin isoform a preproprotein
Malate dehydrogenase,mitochondrial precursor
Human peroxiredoxin 5
Transferrin
Thymosin,   10
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Figure 1: Heat map displaying the expression of 44 proteins in 28 HER2-positive and 11 TNBC tumors. Classiﬁcation of 39 breast cancer
cases into 2 groups based on tumor subtypes (HER-positive tumors and TNBC tumors) by the hierarchical clustering using GEPAS software.
Each column represents a case as labeled on top, the short labeling cases are “TNBC” with sample ID, and long labeling cases are “HER2-
positive” with sample ID. Each row represents a protein ID as indicated at the right. 44 proteins were expressed by ≥2-fold diﬀerences and
detected in ≥50% of the cases in either group.
through conversion of retinol to retinoic acid [27]. ALDH1
is considered to be a breast cancer stem cell marker and
also a predictor for poor prognosis [27]. Because breast
cancer stem cells have been implicated in radiation and
chemotherapy resistance, as well as increasing the potential
for metastasis, our ﬁnding of ALDH1A1 in TNBC may
explain the more frequent relapse in TNBC patients. Pre-
viously, we have observed an overexpression of ALDH1 in
TNBC when compared with hormone-receptor-positive and
HER2-negative breast cancer [28]. In this paper, we also
found a preferential overexpression of ALDH1 in TNBC
over HER2-positive tumors. The unique overexpression of
ALDH1 in TNBC tumors may point out an important
population as the origin of some TNBC whereby notch
signaling-dependent stem cell targets may be leveraged for
target therapy development [29].10 International Journal of Proteomics
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(b) Galectin-3-binding protein
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(c) Complement component 1 inhibitor
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(f) Transferrin
Figure 2: Representative proteins diﬀerentially expressed by HER2+ and TNBC tumors. (a)–(c): proteins preferentially expressed in TNBC.
(d)-(e): proteins preferentially expressed in HER2+ tumors.
Ad i ﬀerent set of proteins was found preferentially ele-
vatedinHER2+tumors.ThislistincludedCK19,transferrin,
transketolase, and thymosin β4a n dβ10, and the biological
signiﬁcance of some of them will be discussed.
Cytokeratins are known to be important in cellular
motility, signaling, and division. While CK8/CK18 were sim-
ilarly detected in both HER2+ and TNBC tumors, elevated
CK19 was more commonly found in HER2+ tumors. Our
observation coincides with the ﬁnding reported by Schulz
et al. using a combination of 2D-DIGE/mass spectrometry
and western blot [30]. Both our current and previous
papers suggest that CK19 is low in TNBC when compared
with either HER2-positive or HER2-negative but hormone-
receptor-positive breast cancer [31]. Although the biological
signiﬁcance and the mechanism of reduced CK19 in TNBC
are not clear, it could be related to the frequent recurrence
and poor overall survival rate seen in TNBC patients [32].
Transferrin, another protein associated with HER2-
positive cancer, is essential for cell growth and iron-
dependent metabolic activities including DNA synthesis,
electron transport, and mitogenic signaling pathways [33].
The elevation of transferrin receptor (CD71) was reported
to be a marker of poor outcome [33]. Vyhlidal et al.
reported that transferrin is regulated by estrogen hormone
[34], and tamoxifen was shown to be ineﬀective in ER-
positive breast cancer with transferrin overexpression which
coincides with the tamoxifen resistance observed in HER2-
positive hormone-receptor-positive breast cancer. Taken
together, the ineﬀectiveness of tamoxifen in women with
HER2-positive and hormone-receptor-positive cancer may
be related to the prevalent expression of transferrin in these
tumors.
Thymosin β4a n dβ10 are members of a family of
highly conserved small acid peptides that control the growth
and diﬀerentiation of many cell types. They act as major
actin-sequestering factor and play a role in cancer cell
motility, invasion and metastasis [35, 36]. Thymosin β4
stimulates tumor metastasis by activating cell migration and
angiogenesis in lung cancer and is associated with poor
prognosis [37–39]. Elevations of thymosin β4a n dβ10 have
also been reported in a number of other cancers including
melanoma and breast cancer [40]. In the same tumor,
the level of thymosin β10 was signiﬁcantly higher in the
cancer cells than in the normal breast parenchymal cells of
the uninvolved area [41]. Its association with high-grade
and poorly diﬀerentiated cancer cells is consistent with our
ﬁndings of thymosin β10 overexpression in HER2-positive
breast cancer. Further studies are required to conﬁrm its12 International Journal of Proteomics
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(a) Cytokeratin-19
(b) (c)
Figure 3: CK19 expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated CK19 expressions found in HER+
tumor group by LC-MS/MS and conﬁrmed by IHC in most of the frozen HER2+ tumors. (a) Normalized spectrum count of CK19 detected
in 39 breast cancer tissues. (b) Immunohistochemical staining of CK19 in a HER2+ frozen tumor (power 200x). (c) Immunohistochemical
staining of CK19 in a TNBC frozen tumor (power 200x).
overexpression and to determine its role in HER2-positive
breast cancer.
In this study, we also reported the MS-identiﬁed protein
signaturepredictingdrug-inducedtumorresponseinHER2-
positive tumors. We found that enolase 1, vimentin, L-
plastin, and ApoD predicted a favorable response of HER2-
positive tumors. In contrast, elevated peroxiredoxin 5 and
heat shock proteins 70 were found in nonresponding HER2-
positive tumors.
Enolase 1(ENO1), a phosphopyruvate dehydratase, is
a key glycolytic enzyme involved in anaerobic metabolism
underhypoxicconditionsofcancergrowth,andacellsurface
plasminogen receptor for tumor invasion. Overexpression
of ENO1 in breast, and lung cancers is associated with
tumor progression and rapid tumor growth [42]. While our
study did not speciﬁcally studying the prognostic value of
ENO1, the observation of ENO1 in HER2-positive tumors
supports the prognostic importance of this molecule. While
it was seen in the more aggressive subtype of breast cancer,
our study showed ENO1 elevation in HER2-positive tumors
seemed to indicate a better tumor response to chemother-
apy.
Vimentin is a member of the intermediate ﬁlament
family. Along with microtubules and actin microﬁlaments,
vimentin is an integral component of the cell cytoskeleton.
In cancer, altered vimentin level is associated with a dedif-
ferentiated phenotype, increased motility, invasiveness, and
poor clinical prognosis [43, 44]. Vimentin overexpression
wasfoundin90.5%ofgradeIIIbreastcarcinomas[45]which
mayexplainitspresenceinbothHER2-positive breastcancer
and in TNBC. Our study found that vimentin, although
an aggressive marker for breast cancer growth, is another
indicator for a favorable tumor response to chemotherapy.
L-plastin is an actin-binding protein involved in cancer cell
migration, invasion, and metastasis, and its expression in
breast cancer cell lines correlates with the degree of inva-
siveness [30, 46]. In this paper, L-plastin overexpression in
HER2-positive breast cancer was associated with a likelihood
of pCR.
In contrast to those molecules associated with favorable
tumor response to neoadjuvant therapy, high levels of Prx V
in HER2-positive breast cancers were found to be associated
with poor response to the same chemotherapy regimen.
Peroxiredoxins (Prxs) represent a novel group of peroxidasesInternational Journal of Proteomics 13
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(a) Galectin-3-binding protein
(b) (c)
Figure 4: G3BP expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated G3BP expressions found in TNBC
group by LC-MS/MS and conﬁrmed by IHC in most of the frozen TNBC tumors. (a) Normalized spectrum count of G3BP detected from 39
breastcancertissues.(b)ImmunohistochemicalstainingofG3BPinaTNBCfrozentumor(power200x).(c)Immunohistochemicalstaining
of G3BP in a HER2+ frozen tumor (power 200x).
containing high antioxidant activity involved in cell diﬀeren-
tiation and apoptosis [47] ,a n dP r xVi sp a r t i c u l a r l ye ﬀective
in reducing reactive oxygen species (ROS). Moreover, Prx V
is found in peroxisomes and mitochondria where protection
againstROSismostlyneeded.TheantioxidantactivityofPrx
V may be associated with drug resistance of the tumor cells.
While some molecules are unique to the characteristics
of individual subtype of breast cancer, Hsp70 overexpression
was found by us to be associated with drug resistance in
both HER2-positive and TNBC tumors. Heat shock proteins
are overexpressed in a wide range of human cancers and are
implicated in tumor cell proliferation, diﬀerentiation, death,
invasion, metastasis, and immune recognition [48]. Consis-
tent with the cellular functions of Hsp70, clinically it has
been correlated with poor prognosis in breast, endometrial,
cervical, and bladder cancers. Others have also reported that
Hsp70 mediated drug resistance through its inhibitory eﬀect
on chemotherapy-induced tumor cell apoptosis [48–50].
In TNBC tumors, a list of diﬀerent proteins was found
to be overexpressed in tumors resistant to neoadjuvant
chemotherapy. In addition to Hsp70, proteins such as
periostin precursor (OSF-2), RhoA, actinin α4, cathepsin D
preproprotein, and annexin 1 predicted a poor response of
TNBC to treatment. Although all of them were known to
have important cancer biological properties, they have not
been linked to chemotherapy susceptibility until now.
Periostinwasoriginallyidentiﬁedinamouseosteoblastic
cell line as an extracellular matrix adhesion protein for pre-
osteoblasts. In addition to forming bones, teeth, and heart,
periostin was recently found to be overexpressed in various
types of human cancer. Periostin interacts with multiple
cell-surface receptors (most notable integrins) and signals
via the PI3-K/Akt and other pathways to promote cancer
cell survival, epithelial-mesenchymal transition, invasion,
and metastasis [51]. In breast cancer, periostin was found
upregulated at both the mRNA and protein levels [51–55].
Activation of the Akt/PKB cellular survival pathway with
consequential protection of tumor cells and endothelial cells
from stress-induced cell death [51, 56]m a yc o n t r i b u t et o
the periostin-mediated drug resistance in cancer. To our
knowledge, this is the ﬁrst paper to link periostin to drug
resistance in TNBC.
RhoA is a member of the Ras superfamily. It is involved
in the regulation and timing of cell division. It is a small
GTPase protein known to regulate the actin cytoskeleton
in the formation of stress ﬁbers. RhoA protein levels were
signiﬁcantly increased in breast cancer compared with the
matched normal tissue. It has been reported by Fritz et al.14 International Journal of Proteomics
that an elevated RhoA protein level correlated with increas-
ing breast tumor grade and poor prognosis [57].
Actinin α4 is another interesting protein that we found
to indicate a poor tumor response to neoadjuvant therapy.
It is thought that the actinin α4 cross-links actin ﬁlaments
and connects the actin cytoskeleton to the cell membrane.
The accumulation of actinin α4 in the cytoplasm is related
to tumor invasiveness and metastasis, probably by enhancing
cell motility, and was suggested to be a novel prognosticator
in patients with ovarian and breast cancer [58].
Cathepsin D, an acid protease, is active in intracellular
protein breakdown and is involved in the pathogenesis of
several diseases. Its preproprotein secreted by cancer cells,
acting as a mitogen on both cancer and stromal cells,
stimulates both proinvasive and prometastatic properties of
cancercells.ManystudiesfoundthatcathepsinDprepropro-
tein/cathepsin D level represents an independent prognostic
factor in a variety of cancers and is, therefore, considered to
be a potential target for anticancer therapy [59]. Others have
also shown that overexpression of cathepsin D in human
breast cancers is associated with a higher risk of relapse and
metastasis [59–61]. In our study, cathepsin D preproprotein
appeared to be a drug-resistant marker in TNBC.
Although many proteins identiﬁed in this pilot study
are interesting with promising potential, this study has
several limitations. First, the tumors used in this study
were collected from a clinical trial which provided many
controlled clinical data; however, the sample size available
for proteomic analysis was small. As a result, the ﬁndings
derived from a small sample size always warrant a cautious
interpretation. Second, the HER2-positive group consisted
of tumors with diﬀerent ER and PR status which might
interferewiththe conclusion. The potential falseassociations
with HER2 might be solved by stratifying the HER2-
positive tumors according to hormonal receptor status in
a larger study. Lastly, the HER2-positive patients in this
study were randomized to receive either chemotherapy
alone or chemotherapy with Herceptin. The selected drug-
resistantmarkersmayrepresenttheresistancenot onlytothe
chemotherapy but also to Herceptin.
In summary, our study has led to the identiﬁcation
of a list of important breast cancer proteins. The study
also suggests that MS-based protein proﬁling may be an
important tool in discovery of cancer biosignatures for
tumor subtyping and prediction of treatment outcome.
When suﬃciently validated, some of these candidate protein
markers could be used to improve breast cancer care. In
addition, due to the heterogeneous and complex nature of
the breast cancer tissue specimens, more reﬁned methods
need to be developed to maximize the protein identiﬁcation
to allow the capture of the best protein candidate markers for
clinical use.
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